Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189729 | 1.00 | EPHX1 (0.39) | EPHX1KDM4CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL21189728 | 0.99 | EPHX1 (0.37) | EPHX1KDM4CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23589098 | 0.90 | EPHX1 (0.38) | EPHX1KDM4CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23588852 | 0.90 | EPHX1 (0.38) | EPHX1KDM4C | |
| SCHEMBL25004241 | 0.90 | EPHX1 (0.38) | EPHX1KDM4C | |
| SCHEMBL22735813 | 0.87 | EPHX1 (0.40) | EPHX1KDM4CPAOX | |
| SCHEMBL21365315 | 0.85 | EPHX1 (0.41) | EPHX1KDM4CCA3CA5ACA5B | |
| SCHEMBL24194642 | 0.84 | EPHX1 (0.38) | EPHX1KDM4C | |
| SCHEMBL22386557 | 0.80 | SMN1; SMN2 (0.36) | EPHX1SMN1; SMN2NPC1RAB9ACA3 | |
| SCHEMBL26616375 | 0.78 | PAOX (0.32) | PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-01-02 | — | — | US | disclosed |
| US-20230381284-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-11793861-B2 | PTH prodrugs | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-10-24 | — | — | US | disclosed |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-10-12 | — | — | US | disclosed |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-09-19 | — | — | US | disclosed |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-09-19 | — | — | US | disclosed |
| US-20230121525-A1 | PTH Prodrugs | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20230042670-A1 | Hypoparathyroidism Treatment | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-02-09 | — | — | US | disclosed |
| US-20220008516-A1 | PTH Prodrugs | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2022-01-13 | — | — | US | disclosed |
| US-20210196801-A1 | Starting Dose of PTH Conjugates | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2021-07-01 | — | — | US | disclosed |
| US-20200376089-A1 | PTH PRODRUGS | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-12-03 | — | — | US | disclosed |
| US-20200360488-A1 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-11-19 | — | — | US | disclosed |
| US-20200360487-A1 | PTH PRODRUGS | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-11-19 | — | — | US | disclosed |
| US-20200276276-A1 | PTH Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2020-09-03 | — | — | US | disclosed |
| US-20190282668-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190224329-A1 | Incremental Dose Finding in Controlled-Release PTH Compounds | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376089-A1 | PTH PRODRUGS | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-20190224329-A1 | Incremental Dose Finding in Controlled-Release PTH Compounds | PTH1R, CALCA, CALCB | EPHX1 2395/4885KDM4C 4498/4885SMN1; SMN2 4124/4885 |
| US-20200276276-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-11793861-B2 | PTH prodrugs | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-20210196801-A1 | Starting Dose of PTH Conjugates | PTH1R, FGF23, PTMS | EPHX1 1259/4885KDM4C 4104/4885SMN1; SMN2 3218/4885 |
| US-20230121525-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | EPHX1 1814/4885KDM4C 4210/4885SMN1; SMN2 4438/4885 |
| US-20190282668-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | EPHX1 1814/4885KDM4C 4210/4885SMN1; SMN2 4438/4885 |
| US-20230381284-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | EPHX1 2811/4885KDM4C 3997/4885SMN1; SMN2 3606/4885 |
| US-20200360487-A1 | PTH PRODRUGS | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | EPHX1 1814/4885KDM4C 4210/4885SMN1; SMN2 4438/4885 |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCB, AVPR2 | EPHX1 3511/4885KDM4C 4616/4885SMN1; SMN2 3277/4885 |
| US-20220008516-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | EPHX1 878/4885KDM4C 2681/4885SMN1; SMN2 4852/4885 |
| US-20230042670-A1 | Hypoparathyroidism Treatment | PTH1R, PTMS, CALCA | EPHX1 2650/4885KDM4C 4218/4885SMN1; SMN2 4153/4885 |
| US-20200360488-A1 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | PTH1R, PTMS, FGF23 | EPHX1 1814/4885KDM4C 4210/4885SMN1; SMN2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.